GENOTYPE-PHENOTYPE CORRELATIONS OF THE COURSE OF CYSTIC FIBROSIS IN RUSSIAN CHILDREN. THE FIRST DESCRIPTION OF ELEVEN NEW MUTATIONS

Background. Cystic fibrosis is a hereditary disease that occurs as a result of mutations in the regulator gene of chloride ion transmembrane transport (CFTR). Finding mutations in the CFTR gene is necessary for identification of the clinical features of cystic fibrosis.

Objective. Our aim was to identify genotype-phenotype correlations between mutations of the first class of pathogenicity and clinical manifestations of cystic fibrosis based on studying the prevalence and structure of CFTR gene mutations.

Methods. The study included children under 18 years with cystic fibrosis admitted to hospital between 2013 and 2017. Biallelic mutations in the CFTR gene were the noninclusion criterion. The CFTR gene variants were analyzed by next-generation sequencing method.

Results. In 125 patients with cystic fibrosis, 59 different variants of the CFTR gene were detected, 11 of them not previously described. The most common was the deletion c.1521_1523del found in 98 (39.2%) of the 250 analyzed CFTR gene alleles and the deletion c.1545_1546del found in 22/250 (8.8%) alleles. It has been shown that the mutation c.1545_1546del, p.Y515* was more often found in children of the Chechen nation — odds ratio (OR) 139 (95% confidence interval 15–1,257). It has been established that meconium ileus, pancreatic deficiency and cirrhosis are more common in patients with mutations of the first category of pathogenicity: OR 3.9 (95% CI 1.0–15.0), 4.4 (95% CI 1.8–11.1), and 351 (95% CI 17.5–7,046), respectively. The association of CFTR gene mutations with the development of bronchiectases and polypous pancinusitis has not been found.

Conclusion. Correlations between the genotype and clinical manifestations of cystic fibrosis in Russian children with CFTR gene mutations of the first class of pathogenicity have been established.

1. Kapranov NI, Kashirskaya NYu. Mucoviscidosis. Moscow: Medpraktika-M; 2014. 672 p. (In Russ).

2. Farrell P. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7(5):450–453. doi: 10.1016/j.jcf.2008.03.007.

3. Krasovsky SA, Chernyak AV, Kashirskaya NYu, et al. Cystic fibrosis in Russian Federation: establishment of the national registry. Pediatriia. 2014;93(4):44–55. (In Russ).

4. Kashirskaya NY, Krasovsky SA, Chernyak AV, et al. Trends in life expectancy of cystic fibrosis patients in Moscow and their connection with the treatment received: retrospective analysis for 1993–2013. Current pediatrics. 2015;14(4):503–508. (In Russ).doi: 10.15690/vsp.v14.i4.1390.

5. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066–1073. doi: 10.1126/science.2475911.

6. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989; 245(4922):1073–1080. doi: 10.1126/science.2570460.

7. genet.sickkids.on.ca [Internet]. Cystic Fibrosis Mutation Database [cited 2017 Dec 24]. Available from: www.genet.sickkids. on.ca/cftr.

8. Audrezet MP, Dabricot A, Le Marechal C, Ferec C. Validation of high-resolution DNA melting analysis for mutation scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. J Mol Diagn. 2008;10(5):424–434. doi: 10.2353/jmoldx.2008.080056.

9. Le Marechal C, Audrezet MP, Quere I, et al. Complete and rapid scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high-performance liquid chromatography (DHPLC): major inplications for genetics counseling. Hum Genet. 2001;108(4):290–298. doi: 10.1007/s004390100490.

10. Galvin P, Clarke L, Harvey S, Amaral M. Microarray analysis in cystic fibrosis. J Cyst Fibros. 2004;3(2):29–33. doi: 10.1016/j.jcf.2004.05.006.

11. Baranov AA, Kapranov NI, Kashirskaya NY, et al. Diagnostic problems of mucoviscidosis and ways of solution in Russia. Pediatric pharmacology. 2014;11(6):16–23. (In Russ). doi: 10.15690/pf.v11i6.1211.

12. Lucarelli M, Narzi L, Piergentili R, et al. A 96-well formatted method for exon and exon/intron boundary full sequencing of the CFTR gene. Anal Biochem. 2006;353(2):226–235. doi: 10.1016/j.ab.2006.03.022.

13. A new targeted CFTR mutation panel based on next-generation sequencing technology. J Mol Diagn. 2017;19(5):788–800. doi: 10.1016/j.jmoldx.2017.06.002.

14. Schrijver I, Rappahahn K, Pique L, et al. Multiplex ligationdependent probe amplification identification of whole exon and single nucleotide deletions in the CFTR gene of Hispanic individuals with cystic fibrosis. J Mol Diagn. 2008;10(4):368–375. doi: 10.2353/jmoldx.2008.080004.

15. Mehdizadeh Hakkak A, Keramatipour M, Talebi S, et al. Analysis of CFTR gene mutations in children with cystic fibrosis, first report from North-East of Iran. Iran J Basic Med Sci. 2013;16(8):918–921.

16. Registry of cystic fibrosis patients in Russian Federation. 2015. Ed by E.I. Kondrat’eva, S.A. Krasovsky, A.Yu. Voronkova, et al. Moscow: Medpraktika-M; 2016, 72 p. (In Russ).

17. Gurwitz D, Corey M, Francis PW. Perspectives in cystic fibrosis. Pediatr Clin North Am. 1979;26(3):603–615. doi: 10.1016/S00313955(16)33752-X.

18. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet. 2003;67(Pt 5):471–485. doi: 10.1046/j.1469-1809.2003.00028.x.

19. Green DM, McDougal KE, Blackman SM, et al. Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients. Respir Res. 2010;11:140. doi: 10.1186/1465-9921-11-140.

20. Bombieri C, Seia M, Castellani C. Genotypes and phenotypes in cystic fibrosis and cystic fibrosis transmembrane regulator-related disorders. Semin Respir Crit Care Med. 2015;36(2):180–193. doi: 10.1055/s-0035-1547318.

21. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2015;16(1):45–56. doi: 10.1038/nrg3849.

22. Elborn JS. Personalised medicine for cystic fibrosis: treating the basic defect. Eur Respir Rev. 2013;22(127):3–5. doi: 10.1183/09059180.00008112.

23. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55(3):403–408. doi: 10.1136/gut.2005.069153.

24. hgmd.cf.ac.uk [Internet]. HGMD® Professional 2017.4. [cited 2018 Feb 20]. Available from: http://www.hgmd.cf.ac.uk/ac/index.php.

25. Odinokova ON. Rasshirennyi poisk mutatsii gena CFTR v vyborke bol’nykh mukovistsidozom iz Sibirskogo regiona. (Conference proceedigs) VII ezhegodnaya Severo-Zapadnaya s mezhdunarodnym uchastiem nauchno-prakticheskaya konferentsiya po muko vistsidozu «Praktika lecheniya mukovistsidoza»; 2016 may 27–28; St. Petersburg. (In Russ). Доступно по: http://ostrovaru.com/%D0%BF%D1%80%D0%BE%D0%B3%D1%80%D0%B0%D0%BC%D0%BC%D1%8B/2015/01/08/%D0%BA%D0%BE%D0%BD%D1%84%D0%B5%D1%80%D0%B5%D0%BD%D1%86%D0%B8%D0%B8%D0%B8-%D1%81%D0%B5%D0%BC%D0%B8%D0%BD%D0%B0%D1%80%D1%8B/. Ссылка активна на 12.02.2018.

26. Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros. 2002; 1(2):51–75. doi: 10.1016/S1569-1993(02)00032-2.

27. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424. doi: 10.1038/gim.2015.30.

28. Kondratyeva EI, Sherman VD, Amelina EL, et al. The clinical and genetic characteristics and outcomes of meconium ileus in cystic fibrosis. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2016;61(6):77–81. (In Russ). doi: 10.21508/1027-4065-2016-61-6-77-81.